Title
Evaluate the Use of Ganciclovir Gel 0.3% for the Treatment of Conjunctivitis Caused by Adenovirus
"Prospective, Interventional, Randomized, Double-masked With the Use of Ganciclovir Gel 0.3% for Treatment of Conjunctivitis Caused by Adenovirus."
Phase
Phase 3Lead Sponsor
Adapt Produtos Oftalmológicos Ltda.Study Type
InterventionalStatus
Unknown statusIndication/Condition
Conjunctivitis Adenovirus.Intervention/Treatment
ganciclovir ...Study Participants
22The purpose of this study is to study the use of ganciclovir gel 0.3% for treatment of conjunctivitis caused by adenovirus.
To evaluate the efficacy and tolerability of ganciclovir ophthalmic gel for the treatment of conjunctivitis comparing to placebo (ophthalmic gel). Visual acuity test and slit lamp examination (biomicroscopy) will be performed at each visit to assess the signs/symptoms and the regression of the disease.
Ophthalmic gel (placebo): applied in affected eye 4 times daily for 10 days
Ophthalmic gel ganciclovir 0,3%: applied in affected eye 4 times daily for 10 days
Ophthalmic gel ganciclovir 0,3%: applied in affected eye 4 times daily for 10 days
ophthalmic gel (placebo)in the study eye
Inclusion Criteria: Patients with eye disease with a clinical diagnosis of adenovirus conjunctivitis. Patients of both gender aged over 18 years. Patients who are not pregnant or nursing. Patients able (legally and mentally) to understand and sign informed consent had been signed. Exclusion Criteria: Patients who are in the presence of corticosteroids, either by topical ocular, periocular, intraocular or systemic, for less than 30 days of enrollment and who can not make a drug suspension. Patients with serious systemic diseases like AIDS, cancer, etc., which in the opinion of the investigator, may put the patient at risk. Patient with a single eye or vision in one eye.